

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM687302

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
RxDataScience, Inc.		11/10/2021	Corporation: DELAWARE
Caerus Marketing Group, LLC		11/10/2021	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Credit Suisse AG		
Street Address:	ELEVEN MADISON AVENUE, 23RD FLOOR		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10010		
Entity Type:	Bank: SWITZERLAND		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	5471274	RXDATASCIENCE	
Registration Number:	5527813	RXDS	
Registration Number:	5698180	RXDATASCIENCE	
Registration Number:	5704067	RXDS	
Registration Number:	5522492	RXDS INSIDE	
Registration Number:	5509770	RXDS INSIDE	
Registration Number:	5509769	RXDS	
Registration Number:	5471245	RXDATASCIENCE	
Registration Number:	5401630	STUDYKIK	
Registration Number:	5412454	STUDYKIK	
Registration Number:	5411471	STUDYKIK	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2023704750		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	Joanna McCall		

OP \$290.00 5471274

Address Line 1: 1025 Connecticut Ave NW, Suite 712
Address Line 2: Cogency Global Inc.
Address Line 4: Washington, D.C. 20036

ATTORNEY DOCKET NUMBER: 1522029

NAME OF SUBMITTER: Adalia Wu

SIGNATURE: /Adalia Wu/

DATE SIGNED: 11/10/2021

Total Attachments: 6

source=Syneos Trademark Filing Form#page3.tif
source=Syneos Trademark Filing Form#page4.tif
source=Syneos Trademark Filing Form#page5.tif
source=Syneos Trademark Filing Form#page6.tif
source=Syneos Trademark Filing Form#page7.tif
source=Syneos Trademark Filing Form#page8.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This FIRST LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of November 10, 2021, (this "Agreement"), among RxDataScience, Inc. and Caerus Marketing Group, LLC (**each, a "Grantor"**) and Credit Suisse AG, as administrative agent and collateral agent (in such capacities, the "Collateral Agent") for the ratable benefit of the Secured Parties.

Reference is made to that certain Pledge and Security Agreement, dated as of August 1, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the "Security Agreement"), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers as defined in the Credit Agreement, dated as of August 1, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the "Credit Agreement"), by and among, inter alios, Syneos Health, Inc., a Delaware corporation (the "Administrative Borrower"), the other borrowers party thereto (each a "Borrower" and collectively with the Administrative Borrower, the "Borrowers"), the Lenders from time to time party thereto, and the Administrative Agent. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.03(c) of the Security Agreement, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement or the Credit Agreement, as applicable.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, **each** Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of **such** Grantor and regardless of where located (collectively, the "IP Collateral"):

(A) all Trademarks, including the Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto but excluding any intent-to-use Trademark application prior to the filing and acceptance of a "Statement of Use", "Declaration of Use", "Amendment to Allege Use" or similar notice and/or filing with respect thereto, only to the extent, if any, that, and solely during the period if any, in which, the grant of such security interest may impair the validity or enforceability, or result in the voiding, of such intent-to-use Trademark application or any registration issuing therefrom under applicable Requirements of Law;

(B) all Patents, including the Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

(C) all Copyrights, including the Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III; **and**

(D) all proceeds of the foregoing;

in each case to the extent the foregoing items constitute Collateral.

SECTION 3. **Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. **Each** Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 4. **Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

RXDATASCIENCE, INC.




DocuSigned by:
Sara Epstein
By: _____
433661137AD740A...
Name: Sara Epstein
Title: Director

CAERUS MARKETING GROUP, LLC

DocuSigned by:
Sara Epstein
By: _____
433661137AD740A...
Name: Sara Epstein
Title: Director

SCHEDULE I

TRADEMARKS

Trademark/Image if any	Application Number Application Date	Registration Number Registration Date	Status	Owner
RXDATASCIENCE 	87509123 6/28/2017	5471274 5/15/2018	Registered	RxDataScience, Inc.
RXDS 	87509072 6/28/2017	5527813 7/13/2018	Registered	RxDataScience, Inc.
RXDATASCIENCE	87509011 6/28/2017	5698180 3/12/2019	Registered	RxDataScience, Inc.
RXDS	87508988 6/28/2017	5704067 3/19/2018	Registered	RxDataScience, Inc.
RXDS INSIDE	87508967 6/28/2017	5522492 7/24/2018	Registered	RxDataScience, Inc.
RXDS INSIDE	87496126 6/19/2017	5509770 7/3/2018	Registered	RxDataScience, Inc.
RXDS	87496100 6/19/2017	5509769 7/3/2018	Registered	RxDataScience, Inc.
RXDATASCIENCE	87496071 6/19/2017	5471245 5/15/2018	Registered	RxDataScience, Inc.
STUDYKIK	87551104 8/1/2017	5401630 2/13/2018	Registered	Caerus Marketing Group, LLC
STUDYKIK 	87551083 8/1/2017	5412454 2/27/2018	Registered	Caerus Marketing Group, LLC
STUDYKIK	87519670 7/7/2017	5411471 2/27/2018	Registered	Caerus Marketing Group, LLC

SCHEDULE II

PATENTS

None.

PATENT APPLICATIONS

None.

SCHEDULE III

COPYRIGHTS

Copyright Title	Registration Number	Registration Date	Owner
StudyKik.com website	TXu002013495	10/19/2016	Caerus Marketing Group, LLC